Stock Financial Ratios, Dividends, Split History

ATROB / Astronics Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price32.04
Volume0.00
Market Cap ($M)939.41
Enterprise Value ($M)1,193.27
Book Value ($M)338.03
Book Value / Share15.77
Price / Book2.85
NCAV ($M)-79.65
NCAV / Share-3.72
Price / NCAV-8.62
Share Statistics
Common Shares Outstanding2 6,792,785
Weighted Average Number Diluted Shares Outstanding Adjustment 734,000
Weighted Average Number Of Shares Outstanding Basic 28,586,000
Weighted Average Number Of Diluted Shares Outstanding 29,320,000
Common Shares Outstanding 21,273,979
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets767.57
Liabilities429.54
Quick Ratio1.55
Current Ratio2.86
Income Statement (mra) ($M)
Sales Revenue Goods Net624,464,000.00
Operating Income30.36
Net Income19.68
Earnings Per Share Diluted0.67
Earnings Per Share Basic0.69
Cash Flow Statement (mra) ($M)
Cash From Operations37.78
Cash from Investing-129.56
Cash from Financing37.78
Identifiers and Descriptors
CUSIP046433207
Central Index Key (CIK)8063

Split History

Stock splits are used by Astronics Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Moving Average Crossover Alert: Astronics Corporation (ATRO)

2018-06-01 zacks
Astronics Corporation (ATRO - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ATRO broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. (15-0)

New Strong Sell Stocks for May 14th

2018-05-14 zacks
Adient plc (ADNT - Free Report) is a designer and manufacturer of seating systems and components. The Zacks Consensus Estimate for its current year earnings has been revised 4.8% downward over the last 60 days. (47-0)

Astronics Corporation's (ATRO) CEO Peter Gundermann on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings and welcome to Astronics Corporation's First Quarter 2018 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. (13-0)

New Strong Sell Stocks for April 18th

2018-04-18 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) is a developer of therapies for neurological disorders. The Zacks Consensus Estimate for its current year earnings has been revised 93.2% downward over the last 60 days. (43-0)

CUSIP: 046433207